Polyendocrine Metabolic Ovarian Syndrome is now the new name for the condition long known as Polycystic Ovary Syndrome, a change announced after a 14-year global effort by experts and people living with the disorder. The rename was built around one central idea: the old label did not fit what researchers now know.
The condition affects 1 in 8 women worldwide and more than 170 million women globally, making the shift more than a terminology update. It is meant to reflect the complexity of the illness and to reduce stigma around a condition that can touch hormones, weight, metabolic and mental health, skin, and the reproductive system. A major international education and awareness campaign will support a three-year transition period before the new name is fully implemented in the 2028 International Guideline update.
The work behind the new pmos meaning was published in The Lancet and drew in more than 50 patient and professional organizations, along with 56 patient and professional organizations listed in the process, multiple international workshops, and more than 22,000 survey responses. Helena Teede, one of the researchers involved, said the group found there is no increase in abnormal cysts on the ovary, and that the diverse features of the condition were often unappreciated. That finding cuts against the old name, which focused attention on cysts that are not actually the defining feature of the disorder.
Teede said it was heartbreaking to see delayed diagnosis, limited awareness and inadequate care for people affected by what she called a neglected condition. She added that while international guidelines have advanced awareness and care, a name change was the next critical step toward recognition and better long-term outcomes. The agreed principles behind the new name were patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and practical implementation.
The long process brought patients and multidisciplinary health professionals into the same conversation across several international workshops, and the final name was shaped by lived experience as much as by laboratory findings. Teede said the change was driven with and for those affected and described it as a landmark moment that should lead to worldwide improvements in clinical practice and research. In plain terms, the pmos meaning is no longer a matter of guesswork: it is meant to replace a misleading label with one that better describes the disease people actually live with.
The timing matters because the transition starts now, but the full switch will not happen overnight. Doctors, patients and health systems will have to live with both names during the three-year rollout, even as the international guideline update in 2028 makes the new term official. That leaves one immediate test for the medical community: whether the new name can do what the old one could not, and help people get diagnosed and treated sooner.
